Institutional shares held 67.4 Million
290K calls
318K puts
Total value of holdings $3.67B
$15.8M calls
$17.3M puts
Market Cap $2.68B
49,084,100 Shares Out.
Institutional ownership 137.25%
# of Institutions 295


Latest Institutional Activity in PTGX

Top Purchases

Q2 2025
Ubs Group Ag Shares Held: 2.5M ($136M)
Q2 2025
Commodore Capital LP Shares Held: 1.08M ($58.6M)
Q2 2025
Adage Capital Partners Gp, L.L.C. Shares Held: 1.09M ($59.6M)
Q2 2025
Bvf Inc Shares Held: 3.21M ($175M)
Q2 2025
Holocene Advisors, LP Shares Held: 530K ($28.9M)

Top Sells

Q2 2025
Price T Rowe Associates Inc Shares Held: 937K ($51.1M)
Q2 2025
New Vernon Capital Holdings Ii LLC Shares Held: 7.2K ($393K)
Q2 2025
Artia Global Partners LP Shares Held: 23K ($1.25M)
Q2 2025
Qube Research & Technologies LTD Shares Held: 69K ($3.76M)
Q2 2025
Eversept Partners, LP Shares Held: 277K ($15.1M)

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.


Insider Transactions at PTGX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
642K Shares
From 14 Insiders
Grant, award, or other acquisition 273K shares
Exercise of conversion of derivative security 369K shares
Sell / Disposition
462K Shares
From 7 Insiders
Payment of exercise price or tax liability 12.6K shares
Bona fide gift 14.4K shares
Open market or private sale 435K shares

Track Institutional and Insider Activities on PTGX

Follow Protagonist Therapeutics, Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTGX shares.

Notify only if

Insider Trading

Get notified when an Protagonist Therapeutics, Inc insider buys or sells PTGX shares.

Notify only if

News

Receive news related to Protagonist Therapeutics, Inc

Track Activities on PTGX